<PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Curated"><PMID Version="1">39396047</PMID><DateCompleted><Year>2024</Year><Month>10</Month><Day>12</Day></DateCompleted><DateRevised><Year>2024</Year><Month>10</Month><Day>18</Day></DateRevised><Article PubModel="Electronic"><Journal><ISSN IssnType="Electronic">2072-1315</ISSN><JournalIssue CitedMedium="Internet"><Volume>43</Volume><Issue>1</Issue><PubDate><Year>2024</Year><Month>Oct</Month><Day>12</Day></PubDate></JournalIssue><Title>Journal of health, population, and nutrition</Title><ISOAbbreviation>J Health Popul Nutr</ISOAbbreviation></Journal><ArticleTitle>Comparative clinical trial of Langenlianqiao oral liquid and Lianhuaqingwen capsule in the treatment of mild cases of coronavirus disease 2019 (COVID-19).</ArticleTitle><Pagination><StartPage>158</StartPage><MedlinePgn>158</MedlinePgn></Pagination><ELocationID EIdType="pii" ValidYN="Y">158</ELocationID><ELocationID EIdType="doi" ValidYN="Y">10.1186/s41043-024-00649-6</ELocationID><Abstract><AbstractText Label="OBJECTIVE" NlmCategory="OBJECTIVE">To evaluate the clinical efficacy of Langenlianqiao (LGLQ) oral liquid treatment and provide a reference basis for the clincal treatment of coronavirus disease 2019 (COVID-19).</AbstractText><AbstractText Label="DESIGN" NlmCategory="METHODS">An experimental clinical study was conducted on three groups with confirmed diagnoses of COVID-19. SITE: This study was conducted at Changde Hospital.</AbstractText><AbstractText Label="PARTICIPANTS" NlmCategory="METHODS">A total of 253 patients were enrolled in this study.</AbstractText><AbstractText Label="METHODS" NlmCategory="METHODS">The patients were divided into the LGLQ treatment group (100 cases), the Lianhuaqingwen (LHQW) treatment group (100 cases) and the placebo control group (53 cases), according to the treatment each group received. The occurrence of major clinical symptoms, the duration of symptom disappearance, the number of days in hospitalisation and the duration of infection were compared among the three groups.</AbstractText><AbstractText Label="RESULTS" NlmCategory="RESULTS">Compared with the placebo control group (10.0 [1.2] d, 9.4 [1.3] d), the duration of infection and hospitalisation effectively decreased in the LGLQ group (6.8 [0.6] d, 7.4 [0.8] d) and the LHQW group (6.8 [1.0] d, 7.3 [1.0] d). Furthermore, the incidence of fatigue in the LGLQ group (4.0%) was lower compared to the LHQW group (14.0%) and the placebo control group (15.1%), but this difference was not statistically significant (P = 0.580 for LGLQ vs. LHQW, P = 0.246 for LGLQ vs. placebo). In the treatment of cough, the LGLQ group showed a significantly different effect compared to both the LHQW group (P = 0.014) and the placebo group (P = 0.016). Additionally, for dry cough specifically, LHQW was effective in reducing its incidence compared to the placebo control group (P &lt; 0.05), while LGLQ showed no statistically significant difference from either LHQW (P = 0.39) or the placebo group (P = 0.14). However, neither the LGLQ group nor the LHQW group showed a reduction in the duration of symptom disappearance in patients with pre-existing symptoms (P &gt; 0.05).</AbstractText><AbstractText Label="CONCLUSIONS" NlmCategory="CONCLUSIONS">Compared with the placebo control group, the LGLQ group showed an improvement in the clinical symptoms of COVID-19 and a decrease in the duration of hospitalisation and infection, which confirmed that the LGLQ treatment had the same antiviral effect as the LHQW treatment. This may provide in-depth insights for antiviral therapy research.</AbstractText><CopyrightInformation>© 2024. The Author(s).</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Yang</LastName><ForeName>Yan-Mo</ForeName><Initials>YM</Initials><AffiliationInfo><Affiliation>Department of Pharmacy, Changde Hospital, Xiangya School of Medicine, Central South University (The first people's hospital of Changde city), No.818 of Renmin Street, Wuling District, Changde, 415000, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Li</LastName><ForeName>Qin-Xuan</ForeName><Initials>QX</Initials><AffiliationInfo><Affiliation>Department of Pharmacy, Changde Hospital, Xiangya School of Medicine, Central South University (The first people's hospital of Changde city), No.818 of Renmin Street, Wuling District, Changde, 415000, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Liu</LastName><ForeName>Yi-Zhao</ForeName><Initials>YZ</Initials><AffiliationInfo><Affiliation>Department of Pharmacy, Changde Hospital, Xiangya School of Medicine, Central South University (The first people's hospital of Changde city), No.818 of Renmin Street, Wuling District, Changde, 415000, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Zhou</LastName><ForeName>Mi</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Department of Pharmacy, Changde Hospital, Xiangya School of Medicine, Central South University (The first people's hospital of Changde city), No.818 of Renmin Street, Wuling District, Changde, 415000, China. zhoumi_zhm@126.com.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D016449">Randomized Controlled Trial</PublicationType><PublicationType UI="D003160">Comparative Study</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2024</Year><Month>10</Month><Day>12</Day></ArticleDate></Article><MedlineJournalInfo><Country>Bangladesh</Country><MedlineTA>J Health Popul Nutr</MedlineTA><NlmUniqueID>100959228</NlmUniqueID><ISSNLinking>1606-0997</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D004365">Drugs, Chinese Herbal</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="C000588632">lianhuaqingwen</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D004365" MajorTopicYN="Y">Drugs, Chinese Herbal</DescriptorName><QualifierName UI="Q000627" MajorTopicYN="N">therapeutic use</QualifierName><QualifierName UI="Q000008" MajorTopicYN="N">administration &amp; dosage</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000093485" MajorTopicYN="Y">COVID-19 Drug Treatment</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008875" MajorTopicYN="N">Middle Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000328" MajorTopicYN="N">Adult</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000086382" MajorTopicYN="Y">COVID-19</DescriptorName><QualifierName UI="Q000628" MajorTopicYN="N">therapy</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D016896" MajorTopicYN="N">Treatment Outcome</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000086402" MajorTopicYN="N">SARS-CoV-2</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000284" MajorTopicYN="N">Administration, Oral</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000368" MajorTopicYN="N">Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006760" MajorTopicYN="N">Hospitalization</DescriptorName></MeshHeading></MeshHeadingList><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">COVID-19, Effectiveness of antiviral treatment</Keyword><Keyword MajorTopicYN="N">Chinese medicine oral liquid</Keyword><Keyword MajorTopicYN="N">Symptom improvement</Keyword><Keyword MajorTopicYN="N">Treatment effect</Keyword></KeywordList><CoiStatement>The authors declare no competing interests.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2023</Year><Month>12</Month><Day>6</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2024</Year><Month>9</Month><Day>27</Day></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2024</Year><Month>10</Month><Day>13</Day><Hour>0</Hour><Minute>31</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2024</Year><Month>10</Month><Day>13</Day><Hour>0</Hour><Minute>30</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2024</Year><Month>10</Month><Day>12</Day><Hour>23</Hour><Minute>20</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2024</Year><Month>10</Month><Day>12</Day></PubMedPubDate></History><PublicationStatus>epublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">39396047</ArticleId><ArticleId IdType="pmc">PMC11479534</ArticleId><ArticleId IdType="doi">10.1186/s41043-024-00649-6</ArticleId><ArticleId IdType="pii">10.1186/s41043-024-00649-6</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Zhu N, Zhang D, Wang W, et al. A novel coronavirus from patients with Pneumonia in China, 2019. N Engl J Med. 2020;382(8):727–33.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7092803</ArticleId><ArticleId IdType="pubmed">31978945</ArticleId></ArticleIdList></Reference><Reference><Citation>Gu YQ. Research progress on chemical composition and clinical efficacy of Lianhua Qingwen Capsule, a traditional Chinese medicine for fighting COVID-19. J Pharm Pract. 2021;39(4):5.</Citation></Reference><Reference><Citation>Furtado RHM, Berwanger O, Fonseca HA, et al. Azithromycin in addition to standard of care versus standard of care alone in the treatment of patients admitted to the hospital with severe COVID-19 in Brazil (COALITION II): a randomised clinical trial. Lancet. 2020;396(10256):959–67.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7836431</ArticleId><ArticleId IdType="pubmed">32896292</ArticleId></ArticleIdList></Reference><Reference><Citation>Horby P, Mafham M, Linsell L, et al. Effect of Hydroxychloroquine in hospitalized patients with Covid-19. N Engl J Med. 2020;383(21):2030–40.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7556338</ArticleId><ArticleId IdType="pubmed">33031652</ArticleId></ArticleIdList></Reference><Reference><Citation>Houston BL, Lawler PR, Goligher EC, et al. Anti-thrombotic therapy to Ameliorate complications of COVID-19 (ATTACC): study design and methodology for an international, adaptive bayesian randomized controlled trial. Clin Trials. 2020;17(5):491–500.</Citation><ArticleIdList><ArticleId IdType="pubmed">32815416</ArticleId></ArticleIdList></Reference><Reference><Citation>Nojomi M, Yassin Z, Keyvani H, et al. Effect of Arbidol (Umifenovir) on COVID-19: a randomized controlled trial. BMC Infect Dis. 2020;20(1):954.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7734453</ArticleId><ArticleId IdType="pubmed">33317461</ArticleId></ArticleIdList></Reference><Reference><Citation>Wang Y, Zhang D, Du G, et al. Remdesivir in adults with severe COVID-19: a randomised, double-blind, placebo-controlled, multicentre trial. Lancet. 2020;395(10236):1569–78.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7190303</ArticleId><ArticleId IdType="pubmed">32423584</ArticleId></ArticleIdList></Reference><Reference><Citation>∆ Y-JD, ∆ S-YW, Gong SS, et al. Recent advances of traditional Chinese medicine on the prevention and treatment of COVID-19 - ScienceDirect. Chin J Nat Med. 2020;18(12):881–9.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7832371</ArticleId><ArticleId IdType="pubmed">33357718</ArticleId></ArticleIdList></Reference><Reference><Citation>Yin F, Shen X. The mechanisms and clinical application of traditional Chinese Medicine Lianhua-Qingwen capsule. Biomed Pharmacother . 2021;142.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8352581</ArticleId><ArticleId IdType="pubmed">34385103</ArticleId></ArticleIdList></Reference><Reference><Citation>Huang K, Zhang P, Zhang Z et al. Traditional Chinese medicine (TCM) in the treatment of viral infections: efficacies and mechanisms. Pharmacol [?] Ther, 2021, (7647): 107843.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8011334</ArticleId><ArticleId IdType="pubmed">33811957</ArticleId></ArticleIdList></Reference><Reference><Citation>Daily C, Homepage. https://covid-19.chinadaily.com.cn/a/202003/24/WS5e795bb6a3101282172816c2.html</Citation></Reference><Reference><Citation>Ren JL, Zhang AH, Wang XJ. Traditional Chinese medicine for COVID-19 treatment[J]. Pharmacol Res, 2020, 155104743.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7128263</ArticleId><ArticleId IdType="pubmed">32145402</ArticleId></ArticleIdList></Reference><Reference><Citation>Sun XJ, Wei KH. Network pharmacology analysis of effective ingredients of traditional Chinese medicine for the treatment of novel coronavirus infection. Chin J Pathogenic Biology. 2024;19(3):371–2.</Citation></Reference><Reference><Citation>Liu L, Wang N, Xu DK, et al. The mechanism of traditional Chinese medicine preparation in the treatment of COVID-19. Chem Life. 2022;42(12):2222–30.</Citation></Reference><Reference><Citation>Luo H, Tang QL, Shang YX, et al. Can Chinese Medicine be used for Prevention of Corona Virus Disease 2019 (COVID-19)? A review of historical classics, Research Evidence and current Prevention Programs[J]. Chin J Integr Med. 2020;26(4):243–50.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7088641</ArticleId><ArticleId IdType="pubmed">32065348</ArticleId></ArticleIdList></Reference><Reference><Citation>B YXA AJZ, C ZB, et al. Bioactive natural compounds against human coronaviruses: a review and perspective. Acta Pharm Sinica B. 2020;10(7):1163–74.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7278644</ArticleId><ArticleId IdType="pubmed">32834947</ArticleId></ArticleIdList></Reference><Reference><Citation>Ye M, Luo G, Ye D et al. Network pharmacology, molecular docking integrated surface plasmon resonance technology reveals the mechanism of Toujie Quwen granules against coronavirus disease 2019 pneumonia[J]. Phytomedicine, 2020, 153401.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7837196</ArticleId><ArticleId IdType="pubmed">33191068</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhengtu L, Li L, Hongxia Z, et al. Radix Isatidis Polysaccharides inhibit Influenza a Virus and Influenza A Virus-Induced inflammation via suppression of host TLR3 signaling in Vitro. Molecules. 2017;22(1):116.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6155848</ArticleId><ArticleId IdType="pubmed">28085062</ArticleId></ArticleIdList></Reference><Reference><Citation>Wu FF, Liu LJ, Tan ZE et al. Research progress on antiviral pharmacological effects and clinical applications of Lianhua Qingwen capsules (granules)[J]. Drug Evaluation Research, 2024, (5).</Citation></Reference><Reference><Citation>Diagnosis and Treatment Program for Novel Coronavirus Infections (Trial Ninth Edition.). http://www.nhc.gov.cn/yzygj/s7653p/202203/a354cb3151b74cfdbac6b2e909f311e6.shtml</Citation></Reference><Reference><Citation>Diagnostic Program for New Coronavirus Pneumonia (Ninth Edition.). http://www.nhc.gov.cn/cms-search/downFiles/ef09aa4070244620b010951b088b8a27.pdf?eqid=c0b5e5f70000092b000000066449e9bb</Citation></Reference><Reference><Citation>Yu X, Wu S, Zhang J, et al. Developing TCM clinical practice guidelines: a comparison between traditional Chinese medicine and western medicine. Integr Med Res. 2023;12(2):100952.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC10176161</ArticleId><ArticleId IdType="pubmed">37187680</ArticleId></ArticleIdList></Reference><Reference><Citation>Ding YW, Zeng LJ, Li RF, et al. Research on the pharmacodynamic effect of Lianhua Qingwen granules against respiratory syncytial virus infection in BALB/c mice . J Guangzhou Univ Chin Med. 2016;33(4):540–4.</Citation></Reference><Reference><Citation>A SZ, C JPBB. A SL, Network pharmacology analysis of the therapeutic mechanisms of the traditional Chinese herbal formula Lian Hua Qing Wen in Corona virus disease 2019 (COVID-19), gives fundamental support to the clinical use of LHQW - ScienceDirect. Phytomedicine, 2020, 79.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7474845</ArticleId><ArticleId IdType="pubmed">32949888</ArticleId></ArticleIdList></Reference><Reference><Citation>Mo HY, Ke CW, Zheng JP, et al. Experimental study on the anti-influenza a virus effect of Lianhua Qingwen capsule in vitro. Chin Traditional Med New Drugs Clin Pharmacol. 2007;18(1):5.</Citation></Reference><Reference><Citation>Sheng N, Lu GJ, Fu Y, et al. Research on the impact of forsythiaside A on the toll-like receptor 4 signaling pathway in mice infected with H9N2 avian influenza . J Beijing Univ Agric. 2020;35(3):7.</Citation></Reference><Reference><Citation>Xu JH, Xue Y, Zhang W, et al. Exploration of the molecular mechanism of Shu Feng Jie Du capsule in the treatment of new coronavirus pneumonia (COVID-19) based on network pharmacology . Chin Traditional Herb Drugs. 2020;51(08):2015–23.</Citation></Reference><Reference><Citation>Jia W, Mao SM, Zhang PP, et al. Research on the in vivo antiviral effect of honeysuckle polysaccharides . J Liaoning Univ Traditional Chin Med. 2018;20(6):3.</Citation></Reference><Reference><Citation>Chen S, Wang J, Wu DL, et al. Exploration of the molecular mechanism of the monarch drug in Lianhua Qingwen for the treatment of COVID-19 based on network pharmacology . Pharm Today. 2021;31(04):263–70.</Citation></Reference></ReferenceList></PubmedData></PubmedArticle>